Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 771

Sort by

Sort Order Select

Journal Articles

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

Vandana Chaturvedi, Nora Lakes, Minh Tran, Natalie Castillo, Michael B. Jordan

Blood (2021) 138 (12): 1034–1039.

https://doi.org/10.1182/blood.2020007930

Published: 2021

Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Blood (2021) 137 (25): 3495–3506.

https://doi.org/10.1182/blood.2020007303

Published: 2021

Includes: Supplemental data

Journal Articles

JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation

Lauren K. Meyer, Katherine C. Verbist, Sabrin Albeituni, Brooks P. Scull, Rachel C. Bassett, Alexa N. Stroh, Heather Tillman, Carl E. Allen, Michelle L. Hermiston, Kim E. Nichols

Blood (2020) 136 (6): 657–668.

https://doi.org/10.1182/blood.2020006075

Published: 2020

Includes: Supplemental data

Journal Articles

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi-Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury

Blood (2020) 135 (20): 1739–1749.

https://doi.org/10.1182/blood.2020004823

Published: 2020

Includes: Supplemental data

Journal Articles

Ruxolitinib for steroid-resistant acute GVHD

Antonio Maria Risitano, Regis Peffault de Latour

Blood (2020) 135 (20): 1721–1722.

https://doi.org/10.1182/blood.2020005364

Published: 2020

Journal Articles

Verruconis gallopava in a patient with myelofibrosis on ruxolitinib

Andrew Hsu, Veronica Ulici

Blood (2020) 135 (14): 1189.

https://doi.org/10.1182/blood.2020004799

Published: 2020

Journal Articles

Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3

Nicole Mollé, Spencer Krichevsky, Pouneh Kermani, Richard T. Silver, Ellen Ritchie, Joseph M. Scandura

Blood (2020) 135 (13): 1062–1066.

https://doi.org/10.1182/blood.2019003050

Published: 2020

Includes: Supplemental data

Journal Articles

Ruxolitinib: gaining more than intended

Graeme Greenfield, Mary Frances McMullin

Blood (2020) 135 (13): 983–984.

https://doi.org/10.1182/blood.2020005135

Published: 2020

Journal Articles

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Jennifer M. O’Sullivan, Angela Hamblin, Christina Yap, Sonia Fox, Rebecca Boucher, Anesh Panchal, Samah Alimam, Helene Dreau, Kieran Howard, Pauline Ware, Nicholas C. P. Cross, Mary Frances McMullin, Claire N. Harrison, Adam J. Mead

Blood (2019) 134 (23): 2107–2111.

https://doi.org/10.1182/blood.2019001861

Published: 2019

Includes: Supplemental data

Journal Articles

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

Blood (2019) 134 (21): 1832–1846.

https://doi.org/10.1182/blood.2019000162

Published: 2019

Includes: Supplemental data

Journal Articles

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4402.

https://doi.org/10.1182/blood-2019-130888

Published: 2019

Journal Articles

Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution

Yunfan Yang, MD, Zhongqing Zou, MD, Ting Liu, MD PhD, Yongqian Jia, PhD, Ting Niu, MD PhD, Huanling Zhu, MD, Yu Wu, MD, Yuping Gong, MD, Hong Chang, MD, Jie Ji, MD, Jian Li, MD, Ling Pan

Blood (2019) 134 (Supplement_1): 5384.

https://doi.org/10.1182/blood-2019-128553

Published: 2019

Journal Articles

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Blood (2019) 134 (Supplement_1): 4237.

https://doi.org/10.1182/blood-2019-125974

Published: 2019

Journal Articles

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Ivy Altomare, MD, Anna Nguyen, PharmD, MPH, Shreekant Parasuraman, BPharm, PhD, Dilan Paranagama, PhD, Jonathan K. Kish, PhD MPH, Kevin Lord, PhD MHS, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 4192.

https://doi.org/10.1182/blood-2019-127442

Published: 2019

Journal Articles

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Claire N Harrison, Professor, Aaron T. Gerds, MD MS, Jean-Jacques Kiladjian, MD PhD, Konstanze Döhner, Sarah A Buckley, MD, Jennifer A. Smith, PhD, Adam R Craig, MD PhD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4175.

https://doi.org/10.1182/blood-2019-129245

Published: 2019

Journal Articles

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Ruben A. Mesa, MD, Moshe Talpaz, MD, Jean-Jacques Kiladjian, MD PhD, Claire N Harrison, Professor, Srdan Verstovsek, MD PhD, Sarah A Buckley, MD, Karisse Roman-Torres, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 4195.

https://doi.org/10.1182/blood-2019-124129

Published: 2019

Journal Articles

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Naveen Pemmaraju, MD, Krishna Gundabolu, MBBS, Kristen Pettit, MD, Moshe Talpaz, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Peter Eisenberg, MD, Hagop Youssoufian, MD, Susan Duggan, RN, MBA, Barbara Wallner, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4178.

https://doi.org/10.1182/blood-2019-130310

Published: 2019

Journal Articles

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Claire N Harrison, Professor, Andrea Patriarca, MD, John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Gary J. Schiller, MD, Brian Leber, MD, Timothy Devos, MD PhD, Sujan Kabir, MD, Adrian Senderowicz, MD, Jennifer Mertz, PhD, Patrick Trojer, PhD, James Shao, MS, Vikas Gupta, MD FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 4164.

https://doi.org/10.1182/blood-2019-128211

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Juan Shen, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 4165.

https://doi.org/10.1182/blood-2019-130069

Published: 2019

Journal Articles

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Jason Gotlib, MD MS, Nashat Gabrail, MD, Casey L. O'Connell, MD, Regina Garcia-Delgado, MD, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, Professor, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 4168.

https://doi.org/10.1182/blood-2019-123546

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Ruxolitinib for steroid-resistant acute GVHD

Verruconis gallopava in a patient with myelofibrosis on ruxolitinib

Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3

Ruxolitinib: gaining more than intended

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Efficacy Analysis of Ruxolitinib in Treatment of 72 Patients with Myelofibrosis in a Chinese Institution

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only